Progress of programmed death-1/programmed death-ligand 1 inhibitors in treatment of triple-negative breast cancer
10.3760/cma.j.cn115355-20210908-00395
- VernacularTitle:程序性死亡受体1及程序性死亡受体配体1抑制剂在三阴性乳腺癌治疗中的研究进展
- Author:
Xin LI
1
;
Haizhen BAI
;
Yuanfei SHAN
;
Jiang XUE
;
Gang GUO
Author Information
1. 内蒙古医科大学附属医院甲状腺乳腺外科，呼和浩特 010010
- Keywords:
Triple-negative breast neoplasms;
Programmed death-1;
Programmed death-ligand 1
- From:
Cancer Research and Clinic
2021;33(12):957-960
- CountryChina
- Language:Chinese
-
Abstract:
Breast cancer is the malignant tumor with the highest incidence among women in the worldwide. The triple-negative breast cancer (TNBC) has the strongest immunogenicity. Because of the lack of clear molecular targets, TNBC is a subtype of breast cancer with more difficulties in the treatment and poorer prognosis compared to other breast cancer subtypes. Blocking the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) signaling pathway has been a hot spot of research and treatment of tumors. PD-1/PD-L1 inhibitors provide new treatment options for TNBC. This article reviews the research progress of PD-1/PD-L1 inhibitors alone or in combination with other drugs in treatment of TNBC, intending to provide the theoretical basis for basic or clinical studies.
